LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a…
WINNIPEG, Manitoba, March 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a…
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS”…
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing…
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial,…
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines…
Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead…
Harmony remains ongoing, with OLE study intended to gain insights into long-term exposure to ADP101 in qualifying patientsMENLO PARK, Calif.,…
-FYARRO™ approved November 22, 2021 and launched February 23, 2022- -FYARRO added to NCCN® Guidelines as the only preferred therapy…
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launchExpanded the robust portfolio of…